It’s great to be around a team of women who share my passion for science,” said Sally Hed, ICT president. All of ICT’s current employees are also female, from PhD-level R&D scientists to college interns.
(PRWEB) June 02, 2016
ImmunoChemistry Technologies (ICT), a Twin Cities-based biotechnology company that has developed proprietary research and life science tools, has named Sally Hed president and chief manager, effective immediately.
Hed has been with the company for 20 years, most recently as V.P. of marketing and sales. Her first role with the company was as a scientist when it was in its start-up phase. Over the next 20 years, she helped develop products and build the company into the profitable business it is today, with double-digit growth, a solid customer base and an international distributor network serving labs all over the world.
As chief manager, Hed will set the strategic direction of the company as well as oversee all of ICT’s day-to-day operations.
ICT develops tools and technologies that enable biomedical researchers to discover new drugs and treatments for cancer and other diseases affecting both animals and humans. ICT is considered a leading supplier of apoptosis detection kits, which help researchers detect apoptosis or programmed cell death in living laboratory cells. ICT also offers diluent and buffer components for ELISA kit development along with consulting services to assist researchers with their own assay development projects. ICT’s products have been cited in over 1,500 scientific publications.
In 2014, the company sold its proprietary and patented FLIVO® technology to a private equity firm. This technology enables the timely assessment of chemotherapy effectiveness in living animals, which may one day revolutionize cancer treatment.
Now solely woman-owned, all of ICT’s current employees are also female, from PhD-level R&D scientists to college interns. “ICT recruits the best and brightest, regardless of gender, but it's great to be around other women who share a passion for science," Hed said.
“I’ve always been interested in biology and seek to understand how cells differentiate into specific tissue types, reproduce, and die. I believe my contributions to ICT and the researchers who use ICT’s products have had a bigger impact on human health than if I had pursued a clinical career.”
Hed earned a bachelor’s degree in genetics and cell biology from the University of Minnesota in 1991 and an MBA from Cardinal Stritch University in 1999.
Hed is taking over the leadership role at ICT after the retirement of its founding partner and president, Brian W. Lee, Ph.D. Dr. Lee and his wife Carol Lee recently sold their interests in ICT to Hed.
Since founding the company in 1994, Dr. Lee served as ICT’s chief executive as well as product developer and lead scientist for assay development. He developed many of ICT’s research products, including its ELISA buffers, caspase detection reagents, FLICA® apoptosis detection kits, and FLIVO® patent. Dr. Lee will assist with the leadership transition and will continue to mentor ICT’s scientific and technical staff.
“Brian’s serious, yet laid-back attitude made ICT’s lab a stimulating and fun place to work,” Hed said. “We are grateful for his scientific and entrepreneurial contributions that helped build ICT to where it is today.”
ICT’s customers include many established and published biomedical research scientists at pharmaceutical companies and leading universities like Harvard, Yale, Vanderbilt, and the University of Minnesota, as well as cancer research centers such as Fred Hutchinson Cancer Research Center, Moffitt Cancer Center, MD Anderson Cancer Center, and research institutions such as the NIH, Howard Hughes Medical Institute, and the Karolinska Institute.